Table 5 |
||||||
|
Disease activity and ANCA titers at presentation, treatment and outcome in study groups. |
||||||
| Patients with idiopathic vasculitides (n = 56) |
Patients with antithyroid DIDs (n = 16) |
|||||
|
|
||||||
| WG n = 29 |
MPA n = 23 |
CSSy n = 4 |
WG n = 1 |
MPA n = 3 |
LLD n = 12 |
|
|
|
||||||
| BVAS |
21.37 |
19.78 |
20.0 |
15 |
13. 0 |
- |
| cANCA, n |
28 |
0 |
0 |
1 |
0 |
0 |
| cANCA, l/titer, median |
128 |
- |
- |
64 |
- |
- |
| pANCA, n |
1 |
23 |
4 |
- |
3 |
12 |
| pANCA,1/titer, median |
64 |
256 |
128 |
- |
128 |
256 |
| Cyclophosphamide, n |
29 |
23 |
4 |
1 |
2 |
0 |
| Only corticosteroids n |
0 |
0 |
0 |
0 |
1 |
2 |
| cANCA after 6 months, 1/ titer, median |
16* |
- |
- |
8 |
- |
- |
| pANCA after 6 months, 1/titer, median |
8 |
16 |
- |
- |
32 |
128 |
| CRF, n |
14 |
10 |
1 |
0 |
1 |
0 |
| TRF, n |
2 |
6 |
0 |
0 |
1 |
0 |
| Lethal outcome, n |
11 |
2 |
0 |
0 |
0 |
0 |
| Patients with relapses, n |
23 |
22 |
2 |
0 |
0 |
0 |
|
|
||||||
|
*Median titer of 23 WG patients, six died at first presentation. BVAS, Birmingham Vasculitis Activity Score; cANCA, cytoplasmic antineutrophil cytoplasmic antibodies; CRF, chronic renal failure; CSS, Churg Strauss syndrome; DID, drug-induced autoimmune disease; LLD, lupus-like disease; MPA, microscopic polyangiitis; pANCA, perinuclear antineutrophil cytoplasmic antibodies; TRF, terminal renal failure; WG, Wegener's granulomatosis. |
||||||
|
Bonaci-Nikolic et al. Arthritis Research & Therapy 2005 7:R1072 doi:10.1186/ar1789 |
||||||
